Osteocyte regulation of bone mineral: a little give and take
- PMID: 22302104
- DOI: 10.1007/s00198-012-1915-z
Osteocyte regulation of bone mineral: a little give and take
Abstract
Osteocytes actively participate in almost every phase of mineral handling by bone. They regulate the mineralisation of osteoid during bone formation, and they are also a major RANKL-producing cell. Osteocytes are thus able to liberate bone mineral by regulating osteoclast differentiation and activity in response to a range of stimuli, including bone matrix damage, bone disuse and mechanical unloading, oestrogen deficiency, high-dose glucocorticoid and chemotherapeutic agents. At least some of these activities may be regulated by the osteocyte-secreted product, sclerostin. There is also mounting evidence that in addition to regulating phosphate homeostasis systemically, osteocytes contribute directly to calcium homeostasis in the mature skeleton. Osteocyte cell death and the local loss of control of bone mineralisation may be the cause of focal hypermineralisation of bone and osteopetrosis, as seen in aging and pathology. The sheer number of osteocytes in bone means that "a little give and take" in terms of regulation of bone mineral content translates into a powerful whole organism effect.
Similar articles
-
Osteocyte-Mediated Translation of Mechanical Stimuli to Cellular Signaling and Its Role in Bone and Non-bone-Related Clinical Complications.Curr Osteoporos Rep. 2020 Feb;18(1):67-80. doi: 10.1007/s11914-020-00564-9. Curr Osteoporos Rep. 2020. PMID: 31953640 Review.
-
The role of osteocytes in targeted bone remodeling: a mathematical model.PLoS One. 2013 May 22;8(5):e63884. doi: 10.1371/journal.pone.0063884. Print 2013. PLoS One. 2013. PMID: 23717504 Free PMC article.
-
Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?Osteoporos Int. 2014 Dec;25(12):2685-700. doi: 10.1007/s00198-014-2808-0. Epub 2014 Jul 17. Osteoporos Int. 2014. PMID: 25030653 Review.
-
Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.Bone. 2016 Oct;91:53-63. doi: 10.1016/j.bone.2016.07.002. Epub 2016 Jul 8. Bone. 2016. PMID: 27402532
-
Evidence for osteocyte regulation of bone homeostasis through RANKL expression.Nat Med. 2011 Sep 11;17(10):1231-4. doi: 10.1038/nm.2452. Nat Med. 2011. PMID: 21909105
Cited by
-
Human osteocyte expression of Nerve Growth Factor: The effect of Pentosan Polysulphate Sodium (PPS) and implications for pain associated with knee osteoarthritis.PLoS One. 2019 Sep 26;14(9):e0222602. doi: 10.1371/journal.pone.0222602. eCollection 2019. PLoS One. 2019. PMID: 31557169 Free PMC article.
-
Current Status of Bone-Forming Therapies for the Management of Osteoporosis.Drugs Aging. 2019 Jul;36(7):625-638. doi: 10.1007/s40266-019-00675-8. Drugs Aging. 2019. PMID: 31066015 Review.
-
Strontium potently inhibits mineralisation in bone-forming primary rat osteoblast cultures and reduces numbers of osteoclasts in mouse marrow cultures.Osteoporos Int. 2014 Oct;25(10):2477-84. doi: 10.1007/s00198-014-2791-5. Epub 2014 Jul 22. Osteoporos Int. 2014. PMID: 25048011 Free PMC article.
-
Osteocyte-derived insulin-like growth factor I is not essential for the bone repletion response in mice.PLoS One. 2015 Jan 30;10(1):e0115897. doi: 10.1371/journal.pone.0115897. eCollection 2015. PLoS One. 2015. PMID: 25635763 Free PMC article.
-
Molecular mechanisms and clinical management of cancer bone metastasis.Bone Res. 2020 Jul 29;8(1):30. doi: 10.1038/s41413-020-00105-1. eCollection 2020. Bone Res. 2020. PMID: 32793401 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical